Law, Policy, and Market Implications of Genetic Profiling in Drug Development
Michael J. Malinowski
Louisiana State University, Baton Rouge - Paul M. Hebert Law Center
Houston Journal of Health Law & Policy, Vol. 2, pp. 31-63, 2002
Completion of a map of the human genome and the explosive emergence of a multitude of complementary technologies ranging from DNA chips to sophisticated software have transformed great expectations for genetic medicine into goals potentially obtainable in the foreseeable future. Drug development now encompasses extensive genetic profiling, a field known as pharmacogenomics, which introduces tremendous potential to increase human health and capital - specially through more precise utilization of pharmaceuticals. Accordingly, the legal, medical and life science communities must rise to the challenge of working through the complexities associated with pharmacogenomics rather than continuing to assume the luxury of time.
JEL Classification: IO, I1, K2, O0Accepted Paper Series
Date posted: May 28, 2003
© 2014 Social Science Electronic Publishing, Inc. All Rights Reserved.
This page was processed by apollo6 in 0.906 seconds